Novo Nordisk fights to keep Medicaid paying for weight-loss drugs
NeutralFinancial Markets

Novo Nordisk is actively working to ensure that Medicaid continues to cover weight-loss drugs, which are crucial for many individuals struggling with obesity. This is significant because access to these medications can greatly impact public health and the management of obesity-related conditions. The outcome of this fight could influence healthcare policies and the availability of effective treatments for millions.
— Curated by the World Pulse Now AI Editorial System